These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 35780453)

  • 21. [SURGICAL TREATMENT OF METASTATIC NON—FUNCTIONING NEUROENDOCRINE TUMORS OF THE PANCREAS].
    Shkarban VP
    Klin Khir; 2016; (7):5-7. PubMed ID: 30256557
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Surgical treatment of gastroentero-pancreatic neuroendocrine tumor].
    Ohtsuka T; Takahata S; Ueda J; Ueki T; Nagai E; Mizumoto K; Shimizu S; Tanaka M
    Gan To Kagaku Ryoho; 2013 Jul; 40(7):843-6. PubMed ID: 23863724
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative Clinical Analysis of Gastroenteropancreatic Neuroendocrine Carcinomas with Liver Metastasis and Primary Hepatic Neuroendocrine Carcinomas.
    Qiu MJ; Chen YB; Bi NR; Yang SL; He XX; Xiong ZF
    Dis Markers; 2018; 2018():9191639. PubMed ID: 30416612
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ASO Author Reflection: Postoperative Chemotherapy for Nonmetastatic, Poorly Differentiated Gastroenteropancreatic Neuroendocrine Carcinomas.
    Schmitz R; Moris D; Strickler JH; Blazer DG
    Ann Surg Oncol; 2020 Dec; 27(Suppl 3):804-805. PubMed ID: 32613368
    [No Abstract]   [Full Text] [Related]  

  • 25. [Median resection of pancreas].
    Kubyshkin VA; Vishnevskiĭ VA; Grishankov SA; Shevchenko TV
    Khirurgiia (Mosk); 2007; (10):10-4. PubMed ID: 18163044
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pre- and intraoperative diagnostic requirements, benefits and risks of minimally invasive and robotic surgery for neuroendocrine tumors of the pancreas.
    Gharios J; Hain E; Dohan A; Prat F; Terris B; Bertherat J; Coriat R; Dousset B; Gaujoux S
    Best Pract Res Clin Endocrinol Metab; 2019 Oct; 33(5):101294. PubMed ID: 31351817
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neuroendocrine tumors of the pancreas: Degree of cystic component predicts prognosis.
    Cloyd JM; Kopecky KE; Norton JA; Kunz PL; Fisher GA; Visser BC; Dua MM; Park WG; Poultsides GA
    Surgery; 2016 Sep; 160(3):708-13. PubMed ID: 27216830
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ASO Author Reflections: Nationwide Experience on Locally Advanced Pancreatic Cancer Surgery After Induction Chemotherapy in the Netherlands: A Stepping Stone for the PREOPANC-4 Trial.
    Stoop TF; Seelen LWF; van 't Land FR; van Eijck CHJ; van Santvoort HC; Besselink MG;
    Ann Surg Oncol; 2024 Apr; 31(4):2658-2659. PubMed ID: 38093164
    [No Abstract]   [Full Text] [Related]  

  • 29. ASO Author Reflections: Morbidity and Outcomes of Primary Tumor Management in Patients with Widely Metastatic Well-Differentiated Small Bowel Neuroendocrine Tumors.
    Nigam A; Untch BR
    Ann Surg Oncol; 2024 Apr; 31(4):2359-2360. PubMed ID: 38252266
    [No Abstract]   [Full Text] [Related]  

  • 30. ASO Author Reflections: Prediction of the Chemotherapy Effect on the Prognosis of Locally Advanced Pancreatic Cancer.
    Tanaka M; Hackert T
    Ann Surg Oncol; 2023 Apr; 30(4):2409-2410. PubMed ID: 36209330
    [No Abstract]   [Full Text] [Related]  

  • 31. Aggressive multi-visceral pancreatic resections for locally advanced neuroendocrine tumours. Is it worth it?
    Abu Hilal M; McPhail MJ; Zeidan BA; Jones CE; Johnson CD; Pearce NW
    JOP; 2009 May; 10(3):276-9. PubMed ID: 19454819
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ASO Author Reflections: Endoscopic Management is Reasonable for <2 cm Duodenal Neuroendocrine Tumors.
    Tran CG; Sherman SK; Howe JR
    Ann Surg Oncol; 2022 Jan; 29(1):85-86. PubMed ID: 34608558
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ASO Author Reflections: A Nomogram to Predict Recurrence after Curative-Intent Resection for Neuroendocrine Liver Metastasis.
    Tsilimigras DI; Xiang JX; Zhang XF; Pawlik TM
    Ann Surg Oncol; 2020 Oct; 27(10):3727-3728. PubMed ID: 32440717
    [No Abstract]   [Full Text] [Related]  

  • 34. Metastatic pancreatic neuroendocrine tumors have decreased somatostatin expression and increased Akt signaling.
    Tran CG; Scott AT; Li G; Sherman SK; Ear PH; Howe JR
    Surgery; 2021 Jan; 169(1):155-161. PubMed ID: 32611516
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ASO Author Reflections: Contact Between T and N Classifications in Pancreatic Neuroendocrine Neoplasms.
    Xu JZ; Wang WQ; Liu L; Yu XJ
    Ann Surg Oncol; 2018 Dec; 25(Suppl 3):814-815. PubMed ID: 30302639
    [No Abstract]   [Full Text] [Related]  

  • 36. Robotic resection of the uncinate process of the pancreas.
    Machado MAC; Surjan R; Basseres T; Makdissi F
    J Robot Surg; 2019 Oct; 13(5):699-702. PubMed ID: 30467703
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ASO Author Reflections: Systemic Inflammatory Markers in Pancreatic Neuroendocrine Tumors.
    Gaitanidis A; Patel D; Kebebew E
    Ann Surg Oncol; 2018 Dec; 25(Suppl 3):874-875. PubMed ID: 30353397
    [No Abstract]   [Full Text] [Related]  

  • 38. ASO Author Reflections: Improving Outcomes and Minimizing Variability in Pancreatic Cancer Care: A Study of Ontario and the United States.
    Saadat LV; Wei AC
    Ann Surg Oncol; 2024 Mar; 31(3):1937-1938. PubMed ID: 37865939
    [No Abstract]   [Full Text] [Related]  

  • 39. ASO Author Reflections: Serum Elastase 1 Level as a Risk Factor for Postoperative Recurrence in Patients with Well-Differentiated Pancreatic Neuroendocrine Neoplasms.
    Nanno Y; Toyama H
    Ann Surg Oncol; 2018 Dec; 25(Suppl 3):800-801. PubMed ID: 30136123
    [No Abstract]   [Full Text] [Related]  

  • 40. Minimally Invasive Techniques for Resection of Pancreatic Neuroendocrine Tumors.
    Fernandez Ranvier GG; Shouhed D; Inabnet WB
    Surg Oncol Clin N Am; 2016 Jan; 25(1):195-215. PubMed ID: 26610782
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.